References
- . Lavie CJ, Milani RV, Mehra, MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585–594
- . Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324–332
- . Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc. 2007;82(5):539–542
- . Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92–100
- . Maroo BP, Lavie CJ, Milani RV. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging. 2008;25(8):649–664
- . Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9(4):239–258
- . Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci. 2005;330(6):295–302
- . Harris WS, Ginsberg HN, Arunakul N, . Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovas Risk. 1997;4(5–6):385–391
- . Davidson MH, Stein EA, Bays HE, ; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/day to simvastatin 40 mg/day in hypertriglyceridemic patients: an 8-week randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–1367
- . Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–1932
- . Bays HE, Maki KC, Doyle RT, Stein E. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Postgrad Med. 2009;121(5):145–150
- . Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98(4A):71i–76i
- . Bays H. Rationale for prescription omega-3-acid ethylester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44:205–246
- . Bays H, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409
- . Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;1:CD003205
- . Sabaté J, Cordero-Macintyre Z, Siapco G, Torabian S, Haddad E. Does regular walnut consumption lead to weight gain? Br J Nutr. 2005;94(5):859–864
- . Itoh M, Suganami T, Satoh N, . Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27(9):1918–1925
- . Good D, Lavie CJ, Ventura HO. Dietary intake of nuts and cardiovascular prognosis. The Ochsner Journal. 2009;9:32–36
- . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455. [errata in Lancet. 2001;357:642 and Lancet. 2007;369:106]
- . GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–1230
- . Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Prescription omega-3-acid ethyl esters: effects on non-high-density lipoprotein cholesterol in combined hyperlipidemic patients when coadministered with escalating doses of atorvastatin. In press. Mayo Clin Proc
- . Rogans JA. More on fish oil. N Engl J Med. 1987;316:624–628